|
|
Volumn 101, Issue 11, 2009, Pages 775-777
|
|
Intraperitoneal therapy for ovarian cancer: Why has it not become standard?
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ANTINEOPLASTIC AGENT;
BEVACIZUMAB;
CARBOPLATIN;
CISPLATIN;
CYCLOPHOSPHAMIDE;
PACLITAXEL;
ADVANCED CANCER;
CANCER COMBINATION CHEMOTHERAPY;
CANCER SURVIVAL;
CLINICAL TRIAL;
DRUG SUBSTITUTION;
DRUG TOLERABILITY;
DRUG WITHDRAWAL;
HUMAN;
KIDNEY DISEASE;
NAUSEA AND VOMITING;
NEUROPATHY;
NOTE;
OVARY CANCER;
PRIORITY JOURNAL;
UNSPECIFIED SIDE EFFECT;
FEMALE;
INFUSION;
INTRAVENOUS DRUG ADMINISTRATION;
MORTALITY;
OVARY TUMOR;
RANDOMIZED CONTROLLED TRIAL;
ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;
CARBOPLATIN;
CISPLATIN;
FEMALE;
HUMANS;
INFUSIONS, INTRAVENOUS;
INFUSIONS, PARENTERAL;
OVARIAN NEOPLASMS;
PACLITAXEL;
RANDOMIZED CONTROLLED TRIALS AS TOPIC;
|
|
EID: 67449105920
PISSN: 00278874
EISSN: 14602105
Source Type: Journal
DOI: 10.1093/jnci/djp151 Document Type: Note |
|
Times cited : (20)
|
|
References (0)
|